A phase 1 dose escalation study of IGM-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies Meeting Abstract
| Authors: | Budde, E.; Gopal, A. K.; Kim, W. S.; Flinn, I. W.; Cheah, C. Y. Y.; Nastoupil, L.; Matasar, M. J.; Diefenbach, C. S.; Gregory, G. P.; Qazi, I.; Pang, C. F.; Leabman, M.; Hernandez, G.; Sison, I.; Keyt, B. A.; Chen, D.; Armand, P. |
| Abstract Title: | A phase 1 dose escalation study of IGM-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398800130 |
| DOI: | 10.1182/blood-2021-153355 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 132 -- Hybrid meeting, also took place online -- Source: Wos |
